Yi Hong Yao
Chief Tech/Sci/R&D Officer bij CELLULAR BIOMEDICINE GROUP, INC.
Profiel
Yi Hong Yao is currently the Chief Scientific Officer at AbelZeta Pharma, Inc. Prior to this, he worked as a Director at Medimmune, Inc. from 2011 to 2015.
Dr. Yao received his graduate degree from Boston University, his doctorate from the University of Kansas, and his undergraduate degree from Fudan University.
Actieve functies van Yi Hong Yao
| Bedrijven | Functie | Begin |
|---|---|---|
| CELLULAR BIOMEDICINE GROUP, INC. | Chief Tech/Sci/R&D Officer | 01-08-2015 |
Eerdere bekende functies van Yi Hong Yao
| Bedrijven | Functie | Einde |
|---|---|---|
| Medimmune, Inc. | Director/Board Member | 01-07-2015 |
Opleiding van Yi Hong Yao
| Boston University | Graduate Degree |
| University of Kansas | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
AbelZeta Pharma, Inc.
 AbelZeta Pharma, Inc. BiotechnologyHealth Technology Cellular Biomedicine Group, Inc. is a holding company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. It specializes in immune cell therapy. The company was founded in 2009 and is headquartered in Rockville, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
